retatrutide approval status 2025 retatrutide fda approval Extreme Side Effects Followed Overdose of Unapproved Weight-Loss Drug retatrutide clinical trials phase approval:

CERTIFICATE OF ANALYSIS Product NameGlycine Propionyl L-Carnitine HCl Test ItemsSpecificationResults AppearanceWhite or off-White powderConformsvisual State of solution98%98.6%visual Specific Rotation-19.51-19.7CP2010 Assay(Dry basis)98%98.6%TITRATION Assay(Glycine)22.023.5%22.7%TITRATION Chloride CI14.6% Heavy metals (Pb)0.0002%0.0001%CP2010 Arsenic (AS2O2)0.0001%0.0001%CP2010 Iron (Fe)0.0002%0.0001%CP2010 Loss on drying0.5%0.31%CP2010 Residue on ignition0.10%0.05%CP2010 Microbial Tests Total Bacteria Count1000500CP2010 Escherichia coli10030CP2010 SalmonellaNegative Negative CP2010 SalmonellaNegative Negative CP2010 ConclusionThe product meets the requirements of factory

That is roughly 37% of the studied dose

a Randomized Clinical Trial

Acta Pharmacol Toxicol (Copenh) 52: 8185, 1983 [DOI] [PubMed] [Google Scholar] 39